ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 0790

CoLchicine for Treatment of OsteoArthritis of the Knee: Clinical Outcomes from a 90-day Double-Blind, Placebo-Controlled Study
Abstract Number: 0791

Optimizing Knee Osteoarthritis Treatment with the Precision Medicine Approach in a Clinical Trial Dataset
Abstract Number: 0792

Radiographic and Pain Outcomes from a Phase 3 Trial (OA-07) Evaluating the Efficacy and Safety of Repeat Lorecivivint Injections over 3 Years in Subjects with Knee OA
Abstract Number: 0793

Secular Changes in Widespread Pain Across Two Generations: The Framingham Heart Study
Abstract Number: 0794

Social Security Work Disability and Its Predictors in Patients with Fibromyalgia: 25 Years of Followup
Abstract Number: 0795

Prevalence of Post-exertional Malaise (PEM) in Adults with Rheumatic Diseases and Relationship with COVID19 Infection
Abstract Number: 0796

Development and Evaluation of Machine Learning Prediction Models for Hospitalizations Due to Opioid-Related Harms Among New Users with Rheumatic and Musculoskeletal Diseases
Abstract Number: 0797

Associations Between Discordance of Disease Activity Indices and Quantitative Sensory Testing Measures of Nociplastic Pain in Patients with Early Rheumatoid Arthritis
Abstract Number: 0798

Acute Activation of the Rat Dorsal Root Ganglion Nociceptive Cells by the Serum of Patients Suffering from Fibromyalgia
Abstract Number: 0799

Peripheral Biomarker Signatures and a Genetic Risk Score Improve the Identification of RA-ILD Beyond Clinical Risk Factors
Abstract Number: 0800

Associations of Rheumatoid Arthritis Polygenic Risk with Age at Onset, Serostatus, and Interstitial Lung Disease
Abstract Number: 0801

Neutrophil Activation as a Novel Marker of Lung Disease in Rheumatoid Arthritis
Abstract Number: 0802

Disease Activity Is Strongly Associated with RA-related Lung Disease and Interstitial Lung Disease in Early RA: Results from a Multicenter, Prospective Cohort Study
Abstract Number: 0803

Serum Adipokines and Interstitial Lung Disease in a Prospective Rheumatoid Arthritis Cohort
Abstract Number: 0804

Serologic and Clinical Predictors of Progressive Pulmonary Fibrosis in Rheumatoid Arthritis-associated Interstitial Lung Disease Progression: A Prospective Longitudinal Cohort

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].